» Articles » PMID: 18722042

Nonhuman Primate Allogeneic Hematopoietic Stem Cell Transplantation by Intraosseus Vs Intravenous Injection: Engraftment, Donor Cell Distribution, and Mechanistic Basis

Overview
Journal Exp Hematol
Specialty Hematology
Date 2008 Aug 30
PMID 18722042
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The traditional intravenous (IV) route of administration for hematopoietic stem cell transplantation (HSCT) may result in inefficient placement of donor cells, possibly contributing to suboptimal engraftment and higher risk of graft-vs-host reactions. In order to perform detailed studies of engraftment and donor cell distribution in an animal model with anatomical similarity to man, we performed the first direct homing/engraftment efficiency comparison between intraosseus (IO) and IV HSCT in allogeneic nonhuman primate animal model to assess the utility and mechanism of donor cell homing after IO delivery.

Materials And Methods: Donor bone marrow (BM) cells labeled with PKH26 membrane dye were transplanted to nonmyeloablative-conditioned nonhuman primate animals. Chimerism was confirmed by polymerase chain reaction amplification of donor-specific short tandem repeat locus.

Results: Compared to the IO route, IV infusion trapped 2.4- to 4.8-fold more donor cells in peripheral organs, including the lung, heart, spleen, kidney, and liver. IO injection resulting in a 6.2-fold increase in donor cells retained in the BM at the site of injection and a 2.7-fold increase in donor cells retained in distant BM sites. A profile of selected cell adhesion molecules (CAMs) demonstrated that after IO HSCT, more donor cells express CAMs that could facilitate BM homing and redistribution to non-injection-side BM cavities. This change in homing efficiency may be clinically significant because IO transplantation in haploidentical recipients enhanced donor cell engraftment when compared to IV delivery.

Conclusion: Our results suggest that IO injection enhances both homing and engraftment in nonhuman primate HSCT.

Citing Articles

Long-term lineage commitment in haematopoietic stem cell gene therapy.

Calabria A, Spinozzi G, Cesana D, Buscaroli E, Benedicenti F, Pais G Nature. 2024; 636(8041):162-171.

PMID: 39442556 PMC: 11618100. DOI: 10.1038/s41586-024-08250-x.


Differential CXCR4 expression on hematopoietic progenitor cells versus stem cells directs homing and engraftment.

Felker S, Shrestha A, Bailey J, Pillis D, Siniard D, Malik P JCI Insight. 2022; 7(9).

PMID: 35531956 PMC: 9090236. DOI: 10.1172/jci.insight.151847.


A Small Key for a Heavy Door: Genetic Therapies for the Treatment of Hemoglobinopathies.

Zittersteijn H, Harteveld C, Klaver-Flores S, Lankester A, Hoeben R, Staal F Front Genome Ed. 2021; 2:617780.

PMID: 34713239 PMC: 8525365. DOI: 10.3389/fgeed.2020.617780.


Mesenchymal Stem Cell Therapy for Diabetic Kidney Disease: A Review of the Studies Using Syngeneic, Autologous, Allogeneic, and Xenogeneic Cells.

Savio-Silva C, Beyerstedt S, Soinski-Sousa P, Casaro E, Balby-Rocha M, Simplicio-Filho A Stem Cells Int. 2021; 2020:8833725.

PMID: 33505469 PMC: 7812547. DOI: 10.1155/2020/8833725.


Imaging of cell-based therapy using Zr-oxine cell labeling for positron emission tomography.

Kurebayashi Y, Choyke P, Sato N Nanotheranostics. 2021; 5(1):27-35.

PMID: 33391973 PMC: 7738941. DOI: 10.7150/ntno.51391.